Market Overview:
The global NK cells market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer and cardiovascular diseases, and the growing demand for targeted therapies. The global NK cells market is segmented on the basis of type, application, and region. On the basis of type, it is divided into mogamulizumab, lorvotuzumab mertansine, and others. Mogamulizumab held a dominant share in 2017 owing to its high efficacy in treating various types of cancer such as leukemia, lymphoma, myeloma etc. On the basis of application, it is segmented into cancer therapy (solid tumors & hematological malignancies), cardiovascular diseases therapy (ischemic heart disease & stroke), and others (autoimmune disorders & transplant rejection). Cancer therapy dominated this market in 2017 due to rising incidences of different types if cancers across globe.
Product Definition:
NK Cells are a type of white blood cell that helps the body fight infection and disease. They are important because they can identify and destroy cells that have been infected or damaged, which helps keep the body healthy.
Mogamulizumab:
Mogamulizumab (GAM-1) is a humanized monoclonal antibody designed for the treatment of patients affected by multiple myeloma and lymphomas. The drug has completed phase II clinical trials with positive outcome and is expected to be launched in near future.
NK cells are one of the most important blood cell types involved in immune surveillance against tumor metastasis, infected organisms, autoimmune diseases as well as foreign particles.
Lorvotuzumab Mertansine:
Lorvotuzumab mertansine is a humanized monoclonal antibody that targets the CD16 receptor. Lorvotuzumab mertansine has been shown to inhibit NK cell-mediated cytotoxicity in vitro and in vivo. The drug has completed phase 2 clinical trial and is currently under phase 3 clinical trial for evaluating its safety and efficacy as a treatment for Non-Ketotic Hyperglycemic Type 1 Diabetes (NKH1D).
Application Insights:
The cancer segment dominated the market in 2017 and is expected to witness lucrative growth over the forecast period. This can be attributed to increasing incidence of various types of cancers, such as lung, breast, colorectal and liver cancer. For instance, according to data published by WHO in 2018 regarding global cancer prevalence rates; around 1 in 6 women and 1 in 5 men are estimated to develop some form of cancer during their lifetime.
NK cells have been proven effective against various types of cancers including lung adenocarcinoma (ADC), non-small cell lung carcinoma (NSCLC), pancreatic ductal adenocarcinoma (PDAC) liver metastasis recurrence skin metastasis prostate tumor bone metastasis brain tumor gastrointestinal stromal tumor head & neck squamous cell carcinoma kidney tumors ureter tumors breast carcinomas hormone refractory Metastatic Breast Cancer (MBC).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of global players, high adoption rate for new therapies, and increasing incidence of cancer and cardiovascular diseases. Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising incidences of cancer and other chronic diseases coupled with growing awareness about available treatment options. Moreover, an increase in per capita income levels will boost demand further due to its cost-effectiveness compared with western medicines. The Asia Pacific held more than 40% share in 2017 as NK cells are found at higher levels among Asian population as compared to white race people from North America or Europe (1).
The U.S., China, Japan dominate clinical trials for novel immunotherapies globally; however emerging countries such as India are catching up fast due to increased focus on drug development by Indian government (2).
Growth Factors:
- Increasing incidence of cancer and other diseases requiring immunotherapy
- Growing demand for adoptive cell therapy
- Rising public awareness about the benefits of NK cells-based therapies
- Technological advancements in isolation and characterization of NK cells
- increasing investment in research and development
Scope Of The Report
Report Attributes
Report Details
Report Title
NK Cells Market Research Report
By Type
Mogamulizumab, Lorvotuzumab Mertansine, Others
By Application
Cancer, Cardiovascular Diseases, Others
By Companies
Chipscreen Biosciences (China), Affimed NV (Netherlands), Altor BioScience Corporation (USA), Innate Pharma SA (France), Takeda Pharmaceutical (Japan), Sorrento Therapeutics Inc. (USA), NantKwest Inc. (USA), Bristol-Myers Squibb (USA), NKT Therapeutics (USA)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global NK Cells Market Report Segments:
The global NK Cells market is segmented on the basis of:
Types
Mogamulizumab, Lorvotuzumab Mertansine, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer, Cardiovascular Diseases, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Chipscreen Biosciences (China)
- Affimed NV (Netherlands)
- Altor BioScience Corporation (USA)
- Innate Pharma SA (France)
- Takeda Pharmaceutical (Japan)
- Sorrento Therapeutics Inc. (USA)
- NantKwest Inc. (USA)
- Bristol-Myers Squibb (USA)
- NKT Therapeutics (USA)
Highlights of The NK Cells Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Mogamulizumab
- Lorvotuzumab Mertansine
- Others
- By Application:
- Cancer
- Cardiovascular Diseases
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the NK Cells Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
NK cells are a type of white blood cell that helps the body fight infection. They work to destroy viruses, bacteria, and other harmful substances.
Some of the key players operating in the nk cells market are Chipscreen Biosciences (China), Affimed NV (Netherlands), Altor BioScience Corporation (USA), Innate Pharma SA (France), Takeda Pharmaceutical (Japan), Sorrento Therapeutics Inc. (USA), NantKwest Inc. (USA), Bristol-Myers Squibb (USA), NKT Therapeutics (USA).
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. NK Cells Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. NK Cells Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. NK Cells Market - Supply Chain
4.5. Global NK Cells Market Forecast
4.5.1. NK Cells Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. NK Cells Market Size (000 Units) and Y-o-Y Growth
4.5.3. NK Cells Market Absolute $ Opportunity
5. Global NK Cells Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. NK Cells Market Size and Volume Forecast by Type
5.3.1. Mogamulizumab
5.3.2. Lorvotuzumab Mertansine
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global NK Cells Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. NK Cells Market Size and Volume Forecast by Application
6.3.1. Cancer
6.3.2. Cardiovascular Diseases
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global NK Cells Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. NK Cells Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global NK Cells Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. NK Cells Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global NK Cells Demand Share Forecast, 2019-2029
9. North America NK Cells Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America NK Cells Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America NK Cells Market Size and Volume Forecast by Application
9.4.1. Cancer
9.4.2. Cardiovascular Diseases
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America NK Cells Market Size and Volume Forecast by Type
9.7.1. Mogamulizumab
9.7.2. Lorvotuzumab Mertansine
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America NK Cells Demand Share Forecast, 2019-2029
10. Latin America NK Cells Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America NK Cells Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America NK Cells Market Size and Volume Forecast by Application
10.4.1. Cancer
10.4.2. Cardiovascular Diseases
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America NK Cells Market Size and Volume Forecast by Type
10.7.1. Mogamulizumab
10.7.2. Lorvotuzumab Mertansine
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America NK Cells Demand Share Forecast, 2019-2029
11. Europe NK Cells Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe NK Cells Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe NK Cells Market Size and Volume Forecast by Application
11.4.1. Cancer
11.4.2. Cardiovascular Diseases
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe NK Cells Market Size and Volume Forecast by Type
11.7.1. Mogamulizumab
11.7.2. Lorvotuzumab Mertansine
11.7.3. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe NK Cells Demand Share, 2019-2029
12. Asia Pacific NK Cells Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific NK Cells Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific NK Cells Market Size and Volume Forecast by Application
12.4.1. Cancer
12.4.2. Cardiovascular Diseases
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific NK Cells Market Size and Volume Forecast by Type
12.7.1. Mogamulizumab
12.7.2. Lorvotuzumab Mertansine
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific NK Cells Demand Share, 2019-2029
13. Middle East & Africa NK Cells Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa NK Cells Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa NK Cells Market Size and Volume Forecast by Application
13.4.1. Cancer
13.4.2. Cardiovascular Diseases
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa NK Cells Market Size and Volume Forecast by Type
13.7.1. Mogamulizumab
13.7.2. Lorvotuzumab Mertansine
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa NK Cells Demand Share, 2019-2029
14. Competition Landscape
14.1. Global NK Cells Market: Market Share Analysis
14.2. NK Cells Distributors and Customers
14.3. NK Cells Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Chipscreen Biosciences (China)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Affimed NV (Netherlands)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Altor BioScience Corporation (USA)
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Innate Pharma SA (France)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Takeda Pharmaceutical (Japan)
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Sorrento Therapeutics Inc. (USA)
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. NantKwest Inc. (USA)
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Bristol-Myers Squibb (USA)
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. NKT Therapeutics (USA)
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
